Novavax says protein vaccine works for kids as young as 12

By The Associated Press

Novavax says its COVID-19 vaccine is proving safe and effective for kids as young as 12. The Maryland-based company makes a protein-based vaccine that’s been cleared for use in adults in parts of the world including Britain and Europe, and is under review in the U.S.  Novavax studied more than 2,000 U.S. kids ages 12 to 17 last summer. The company announced Thursday that the shots were 80% effective at preventing symptomatic COVID-19, and it plans to seek expanded use of the vaccine down to age 12.